These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 15203725)

  • 1. Histological markers that predict clinical recurrence in ductal carcinoma in situ of the breast: an Australian population-based study.
    Provenzano E; Hopper JL; Giles GG; Marr G; Venter DJ; Armes JE
    Pathology; 2004 Jun; 36(3):221-9. PubMed ID: 15203725
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Carcinoma in situ of the female breast. A clinico-pathological, immunohistological, and DNA ploidy study.
    Ottesen GL
    APMIS Suppl; 2003; (108):1-67. PubMed ID: 12874968
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitative nuclear morphometry by image analysis for prediction of recurrence of ductal carcinoma in situ of the breast.
    Hoque A; Lippman SM; Boiko IV; Atkinson EN; Sneige N; Sahin A; Weber DM; Risin S; Lagios MD; Schwarting R; Colburn WJ; Dhingra K; Follen M; Kelloff GJ; Boone CW; Hittelman WN
    Cancer Epidemiol Biomarkers Prev; 2001 Mar; 10(3):249-59. PubMed ID: 11303595
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimal management of ductal carcinoma in situ of the breast.
    Sakorafas GH; Farley DR
    Surg Oncol; 2003 Dec; 12(4):221-40. PubMed ID: 14998563
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ductal carcinoma in situ (DCIS) of the breast: evolving perspectives.
    Sakorafas GH; Tsiotou AG
    Cancer Treat Rev; 2000 Apr; 26(2):103-25. PubMed ID: 10772968
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Defining negative margins in DCIS patients treated with breast conservation therapy: The University of Chicago experience.
    Sahoo S; Recant WM; Jaskowiak N; Tong L; Heimann R
    Breast J; 2005; 11(4):242-7. PubMed ID: 15982389
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Histological type and marker expression of the primary tumour compared with its local recurrence after breast-conserving therapy for ductal carcinoma in situ.
    Bijker N; Peterse JL; Duchateau L; Robanus-Maandag EC; Bosch CA; Duval C; Pilotti S; van de Vijver MJ
    Br J Cancer; 2001 Feb; 84(4):539-44. PubMed ID: 11207051
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Histopathological and cell biological characteristics of ductal carcinoma in situ (DCIS) of the breast-a comparison between the primary DCIS and subsequent ipsilateral and contralateral tumours.
    Idvall I; Ringberg A; Anderson H; Akerman M; Fernö M
    Breast; 2005 Aug; 14(4):290-7. PubMed ID: 16085235
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Value of the Van Nuys Prognostic Index in prediction of recurrence of ductal carcinoma in situ after breast-conserving surgery.
    Boland GP; Chan KC; Knox WF; Roberts SA; Bundred NJ
    Br J Surg; 2003 Apr; 90(4):426-32. PubMed ID: 12673743
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 259 Patients with DCIS of the breast applying USC/Van Nuys prognostic index: a retrospective review with long term follow up.
    Di Saverio S; Catena F; Santini D; Ansaloni L; Fogacci T; Mignani S; Leone A; Gazzotti F; Gagliardi S; De Cataldis A; Taffurelli M
    Breast Cancer Res Treat; 2008 Jun; 109(3):405-16. PubMed ID: 17687650
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factors associated with local recurrence and cause-specific survival in patients with ductal carcinoma in situ of the breast treated with breast-conserving therapy or mastectomy.
    Vargas C; Kestin L; Go N; Krauss D; Chen P; Goldstein N; Martinez A; Vicini FA
    Int J Radiat Oncol Biol Phys; 2005 Dec; 63(5):1514-21. PubMed ID: 16005576
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent advances and current controversies in the management of DCIS of the breast.
    Sakorafas GH; Farley DR; Peros G
    Cancer Treat Rev; 2008 Oct; 34(6):483-97. PubMed ID: 18490111
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The treatment of ductal carcinoma in situ (DCIS) of the breast].
    Westenberg AH; Rutgers EJ; Peterse JL; Hendriks JH; Beex LV; van Tienhoven G
    Ned Tijdschr Geneeskd; 2003 Nov; 147(44):2157-61. PubMed ID: 14626831
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic significance of oncogenic markers in ductal carcinoma in situ of the breast: a clinicopathologic study.
    Altintas S; Lambein K; Huizing MT; Braems G; Asjoe FT; Hellemans H; Van Marck E; Weyler J; Praet M; Van den Broecke R; Vermorken JB; Tjalma WA
    Breast J; 2009; 15(2):120-32. PubMed ID: 19292797
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Bilateral ductal carcinoma in situ of the breast: independent events or bilateral disease?].
    André G; Tunon-de-Lara C; Macgrogan G; Laharie-Mineur H; Bussieres JE; Valentin F; Barreau B; Dilhuydy MH; Dilhuydy JM; Mauriac L; Debled M; Durand M; Mathoulin S; Avril A
    J Gynecol Obstet Biol Reprod (Paris); 2007 May; 36(3):260-6. PubMed ID: 17376610
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in-situ: ten-year results of European Organisation for Research and Treatment of Cancer randomized phase III trial 10853--a study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group.
    ; ; Bijker N; Meijnen P; Peterse JL; Bogaerts J; Van Hoorebeeck I; Julien JP; Gennaro M; Rouanet P; Avril A; Fentiman IS; Bartelink H; Rutgers EJ
    J Clin Oncol; 2006 Jul; 24(21):3381-7. PubMed ID: 16801628
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of ductal carcinoma in situ of the breast: review of recent advances and future prospects.
    Mokbel K
    Int J Fertil Womens Med; 2003; 48(5):217-25. PubMed ID: 14626378
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ductal carcinoma in situ in core biopsies containing invasive breast cancer: correlation with extensive intraductal component and lumpectomy margins.
    Dzierzanowski M; Melville KA; Barnes PJ; MacIntosh RF; Caines JS; Porter GA
    J Surg Oncol; 2005 May; 90(2):71-6. PubMed ID: 15844190
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Evaluation of predictive factors, particularly the Van Nuys index, of local recurrence in ductal carcinoma in situ of the breast: study of 166 cases with conservative treatment and review of the literature].
    Denoux Y; Marnay J; Crouet H; Boute V; Delozier T; Vie B; Chasle J
    Bull Cancer; 2001 Apr; 88(4):419-25. PubMed ID: 11371378
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of concurrent proliferative high-risk lesions on the risk of ipsilateral breast carcinoma recurrence and contralateral breast carcinoma development in patients with ductal carcinoma in situ treated with breast-conserving therapy.
    Adepoju LJ; Symmans WF; Babiera GV; Singletary SE; Arun B; Sneige N; Pusztai L; Buchholz TA; Sahin A; Hunt KK; Meric-Bernstam F; Ross MI; Ames FC; Kuerer HM
    Cancer; 2006 Jan; 106(1):42-50. PubMed ID: 16333852
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.